Follicle Stimulating Hormone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application (Infertility Treatment, Assisted Reproductive Application, Others), By Region & Competition, 2021-2031F

The Global Follicle Stimulating Hormone Market is projected to expand from USD 1.91 Billion in 2025 to USD 2.69 Billion by 2031, achieving a compound annual growth rate of 5.87%. Produced by the anterior pituitary gland, follicle stimulating hormone is a vital gonadotropin that orchestrates the development of ovarian follicles in women and regulates spermatogenesis in men. The market is primarily propelled by rising infertility rates and a cultural trend toward postponing childbirth, both of which increase the reliance on assisted reproductive technologies. This surge in demand is corroborated by demographic shifts showing a global reduction in natural birth rates; for instance, the American Society for Reproductive Medicine noted in 2025 that the average global fertility rate stood at 2.2 births per woman in 2024.

Despite these favorable demand drivers, the market encounters significant obstacles stemming from the exorbitant costs of fertility treatments and the scarcity of adequate insurance coverage in numerous areas. These financial hurdles limit patient access to essential therapies and generate marked inequalities in treatment availability across various economic regions, ultimately retarding the market's potential growth.

Market Driver

The rising adoption of Assisted Reproductive Technologies (ART) acts as a primary engine for market growth, given that procedures like In Vitro Fertilization (IVF) depend heavily on exogenous gonadotropins to stimulate controlled ovarian hyperstimulation. In these clinical scenarios, Follicle Stimulating Hormone is crucial for recruiting multiple ovarian follicles, which maximizes the harvest of viable oocytes and enhances the likelihood of conception. This medical requirement creates a steady demand for pharmaceuticals as treatment volumes increase worldwide; notably, the Human Fertilisation and Embryology Authority reported in June 2024 that IVF cycles in the UK rose to approximately 77,000 in 2022, representing an 11% increase over pre-pandemic figures.

Concurrently, the societal trend toward delayed childbearing intensifies the need for these medical interventions, as increased maternal age is associated with lower ovarian reserves and compromised oocyte quality. This demographic shift necessitates the use of higher-dosage FSH protocols to secure successful pregnancy results. The severity of this need is highlighted by data from East Asia, where Statistics Korea reported in August 2024 that the total fertility rate plummeted to a historic low of 0.72 children per woman in 2023. Consequently, this demand fosters a strong commercial landscape, illustrated by Organon's 2024 report indicating a 5% revenue increase in its Women's Health segment during the third quarter, largely attributed to the robust sales of fertility products.

Market Challenge

The high expenses linked to fertility treatments present a major hurdle that constrains the growth of the Global Follicle Stimulating Hormone Market. As follicle stimulating hormone is a key pharmaceutical ingredient in assisted reproductive technology regimens, the steep price of these procedures restricts the potential patient population to those with substantial financial resources. This economic exclusion results in fewer treatment cycles being initiated worldwide, which directly suppresses demand for the hormone and limits overall market revenue. The financial strain is especially severe in areas without strong public healthcare support, compelling patients to cover costs out-of-pocket and frequently leading to high rates of treatment discontinuation.

Moreover, the absence of comprehensive insurance coverage worsens this issue by expanding the divide between clinical necessity and access to care. Lacking financial aid, the accumulated costs of required multiple cycles become unaffordable for most people, effectively limiting market reach. As reported by the American Society for Reproductive Medicine in 2024, the average cost for a single in vitro fertilization cycle in the United States fell between $12,000 and $15,000. This significant financial demand underscores the gravity of the economic barriers that hinder widespread usage and impede the market's growth trajectory.

Market Trends

The introduction and commercialization of biosimilar FSH therapies are fundamentally transforming the competitive environment by offering more affordable alternatives to traditional recombinant products. As patents on leading originator biologics expire, manufacturers of biosimilars are aggressively gaining market share through lower pricing, forcing established companies to offer steeper discounts to keep their formulary spots. This trend of price erosion is cutting into the revenue of legacy brands while simultaneously making fertility treatments more accessible by reducing cycle costs. For example, Organon revealed in its February 2025 report that global sales of its flagship fertility product, Follistim AQ, fell by 10% throughout 2024, a decline largely blamed on competitive discounting and heightened global rivalry.

At the same time, the incorporation of artificial intelligence into precision dosing strategies is revolutionizing ovarian stimulation by facilitating highly customized treatment protocols. Medical professionals are increasingly utilizing AI-based algorithms to evaluate patient-specific biomarkers, such as baseline hormone levels and follicle counts, to determine the ideal FSH dosage for each cycle. This technological advancement reduces the risk of ovarian hyperstimulation syndrome and enhances oocyte retrieval efficiency by abandoning generic, standardized dosing methods. According to a May 2025 article in the Journal of IVF-Worldwide, the usage of AI tools by fertility specialists for tasks like precision dosing and embryo selection increased to approximately 29.2% in 2025.

Key Market Players

• Merck KgAa
• Creative BioMart inc.
• Midas Pharma GmbH
• Genpharm Services
• Livzon Pharmaceutical Group Inc
• Shanghai Techwell Biopharmaceutical Co., Ltd
• Medix Biochemica USA Inc.
• Biogenix Inc.Pvt.Ltd.

Report Scope

In this report, the Global Follicle Stimulating Hormone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Follicle Stimulating Hormone Market, By Type

• Recombinant FSH
• Urinary FSH

Follicle Stimulating Hormone Market, By Application

• Infertility Treatment
• Assisted Reproductive Application (ART)
• Others

Follicle Stimulating Hormone Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Follicle Stimulating Hormone Market.

Available Customizations:

Global Follicle Stimulating Hormone Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).